To the Editor:

Rhinovirus infection is a common trigger of bronchiolitis and early wheezing in children.[@bib1] Its detection is clinically important because rhinovirus-induced bronchiolitis/early wheezing probably is an important risk factor for recurrent wheezing and childhood asthma.[@bib1], [@bib2] The mechanisms behind the undesirable long-term sequela remain poorly understood, but potential factors include atopic inheritance, weak antiviral defense, and viral factors.[@bib3]

Looking closely at previous reports on quantitative rhinovirus detection, we did not find any on the rhinovirus genomic load in bronchiolitis and short-term clinical outcomes, including the need for intensive care treatment. In other conditions, however, higher rhinovirus genomic load is related to the severity and/or duration of acute lower respiratory tract illness, and 1 study reported that it discriminated the response to systemic corticosteroids in terms of less recurrent wheezing.[@bib1], [@bib4], [@bib5] Data on the link between rhinovirus genomic load and clinical outcomes, however, are discordant because studies in subjects with asthma have not shown any clinical association.[@bib6] For these reasons and the relatively small samples in earlier studies, we examined the clinical significance of rhinovirus genomic load in bronchiolitis in 694 children with severe bronchiolitis. Our aim was to prospectively investigate whether rhinovirus genomic load in standardized nasopharyngeal aspirate (NPA) samples is associated with short-term outcomes of bronchiolitis. On the basis of previous literature, our hypothesis was that higher rhinovirus genomic load in bronchiolitis is associated with worse short-term outcomes.

For this analysis, we combined data from 2 multicenter prospective cohort studies of children younger than 2 years hospitalized for bronchiolitis; both studies used the same protocol. The US study[@bib7] was carried out at 16 sites across 12 US states during the 2007-2010 winter seasons (Multicenter Airway Research Collaboration \[MARC\]-30 USA) (see [Table E1](#tblE1){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#interref0010}), whereas the Finnish counterpart study[@bib8] was carried out in 3 Finnish sites during the 2008-2010 winter seasons (MARC-30 Finland). See more details of the MARC-30 and recruitment in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0010}. The study protocol was approved by the ethics committees of participating hospitals, and the study was commenced only after obtaining written informed consent from the guardian.

Investigators interviewed a guardian using a standard questionnaire and conducted a hospital chart review for further clinical data. NPA sampling was performed using a standardized protocol. Samples were stored at −80°C for later virus diagnostics, which included real-time PCR for adenovirus, coronaviruses NL-63, HKU1, OC43, and 229E, enterovirus, human metapneumovirus, influenza virus types A and B, 2009 novel H1N1, parainfluenza virus types 1, 2, and 3, rhinovirus, respiratory syncytial virus (RSV) A and B, *Bordetella pertussis*, and *Mycoplasma pneumonia*, as previously described.[@bib7] Rhinovirus genomic load was quantified by using real-time RT-PCR as the number of amplification cycles needed for a positive PCR test result (cycle threshold \[CT\]). CT values provide a semi-quantitative measure of genomic load, with a highly significant inverse linear relationship between genomic load and CT values. See more details of the virus diagnostics in this article\'s [Methods](#appsec1){ref-type="sec"} section in the Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0015}.

Our primary outcome measure was hospital length of stay (LOS) of 3 days or more.[@bib7], [@bib8] The secondary outcome measure was *intensive care treatment*, defined as use of mechanical ventilation (continuous positive airway pressure and/or intubation during inpatient stay regardless of location) and/or admission to the intensive care unit.[@bib9] Tertiles of rhinovirus CT values permitted classification into 3 rhinovirus genomic load groups: low (CT ≥ 32.7), intermediate (CT, 27.2-32.6), and high (CT \< 27.2). The association between rhinovirus genomic load and the outcomes was analyzed using unadjusted and multivariable logistic regression models. Several sensitivity analyses were performed to assess the robustness of the findings. All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). See more details of the outcomes and statistical methods in the Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0020}.

Of 2615 enrolled children with bronchiolitis from 19 sites, 694 children (27%) had rhinovirus and comprised the analytic cohort (564 US children and 130 Finnish children). Among these children, the median age was 6 months (interquartile range, 3-12 months), 63% were boys, and 46% were non-Hispanic white. Two hundred sixty (37%) children had an LOS of 3 days or more, and 102 (15%) required intensive care treatment. See more details of demographics and clinical course in [Table E2](#tblE2){ref-type="table"}, [Table E3](#tblE3){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0025}.

Overall, there was no significant association between rhinovirus genomic load (an inverse of the CT value) and risk of LOS of 3 days or more or risk of intensive care treatment, either in unadjusted analyses or in multivariable models adjusting for 8 patient-level variables and clustering of patients within sites (all *P* ≥ .40, [Fig 1](#fig1){ref-type="fig"} , *A*; see [Table E4](#tblE4){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0030}). Likewise, a sensitivity analysis focused on the first episode in infants younger than 12 months showed no significant associations (all *P* \> .30; see [Table E4](#tblE4){ref-type="table"}). Similarly, rhinovirus genomic load had no significant associations with the outcomes, by country (see [Fig E1](#dfig1){ref-type="fig"}, *A* and *B*, in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0035}), coinfection (see [Table E5](#tblE5){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0040}), atopy status ([Fig 1](#fig1){ref-type="fig"}, *B*; see [Table E6](#tblE6){ref-type="table"}, [Table E7](#tblE7){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0045}), comorbid status (see [Table E8](#tblE8){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0050}), or respiratory distress severity score (see [Table E9](#tblE9){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0055}).Fig 1The relation between rhinovirus CT value and hospital LOS overall **(A)** and by atopic status **(B)** in children hospitalized for bronchiolitis.

In summary, we found no association between rhinovirus genomic load and short-term outcomes of bronchiolitis. Our hypothesis was justified on the basis of previous clinical data,[@bib1], [@bib4], [@bib5] which were also supported by *in vitro* data.[@bib3] Although multiple viral infections are relatively common in severe bronchiolitis (15% to 30%),[@bib7], [@bib8] the interplay between viruses is poorly understood. Coinfection with RSV and rhinovirus has been linked to more severe short-term outcomes of bronchiolitis compared with RSV alone,[@bib7] but we found no link between rhinovirus genomic load, coinfections, and these same outcomes. Even when examining the rhinovirus-only group, the association was null. Moreover, investigation of the interaction between the rhinovirus genomic load and atopic status was interesting because atopic children appear to be more susceptible than nonatopic children to rhinovirus-induced wheezing.[@bib2]

Considering the large sample size, careful standardization of NPA sampling, and virus diagnostics done with the same protocol in a single laboratory, our results truly suggest no significant association between rhinovirus genomic load and an LOS of 3 days or more or need for intensive care treatment. Although 1 study suggested that rhinovirus genomic load has more clinical relevance in children older than 12 months,[@bib4] this association is not supported by our data or other reports.[@bib5] Because our results contrast the direct association between RSV genomic load and short-term outcomes of bronchiolitis,[@bib10] we speculate that a host response to infection may be more important than virus load in determining the short-term clinical course of rhinovirus-induced bronchiolitis.[@bib3]

The study has potential limitations. First, bronchiolitis is a clinical diagnosis without a common international definition,[@bib11] so we included children up to age 2 years with recurrent wheezing. Results, however, remained consistent when the analysis was restricted to children experiencing their first episode of breathing difficulty during infancy (age \<12 months). Second, clinical decisions (eg, hospital admission/discharge or intensive care treatment) were not based on standardized criteria, which may have caused further variability of care. However, the significant association persisted after adjusting for clustering at the hospital level. Third, one might argue that samples from the upper respiratory tract do not reflect conditions in the lower respiratory tract and that nasal airway epithelial cells may respond differently than bronchial epithelial cells to rhinovirus infections.[@bib12] To our knowledge, there are no data on the comparison of rhinovirus genomic load between upper and lower airway samples and their relation to symptoms. Fourth, one could also argue whether we measured the peak of rhinovirus replication due to lack of longitudinal sampling. A peak in virus concentration typically occurs at 48 to 72 hours after infection in experimental models.[@bib13] Because the duration of prehospital symptoms is typically 1 to 3 days in rhinovirus-induced bronchiolitis,[@bib2] our time window of the first 24 hours of the hospitalization may have been optimal. Fifth, we did not sequence rhinoviruses.[@bib14], [@bib15] Last, the results may not be generalizable to outpatient clinics because all our study subjects were hospitalized.

Challenges in future studies include more careful standardization of analysis (ie, standardization to housekeeping gene), investigation of viremia (ie, links to more compromised clinical outcome), virus genotyping (ie, rhinovirus species and rapid evolution of the virus), and more careful analysis of the replication/transcription status of the virus (ie, separate analysis of positive- and negative-stranded virus RNA).[@bib5], [@bib6] Our findings call attention to the need for more detailed analysis of virology, along with host response and genetics, when investigating predictors of short-term outcomes of severe rhinovirus-induced bronchiolitis.

Methods {#appsec1}
=======

Study design, setting, and subjects {#appsec1.1}
-----------------------------------

The present analysis combines data from 2 multicenter prospective cohort studies of children hospitalized for bronchiolitis. Using a similar protocol, one study was from the United States[@bibE1] and the other was from Finland.[@bibE2] Both studies were performed as part of MARC. MARC is a program of the Emergency Medicine Network ([www.emnet-usa.org](http://www.emnet-usa.org){#intref0060}), a collaboration with more than 225 participating hospitals. The study design, setting, participants, and methods of data collection used in the studies have been reported previously.[@bibE1], [@bibE2] Using a standardized protocol, we enrolled children younger than 2 years hospitalized for an attending physician\'s diagnosis of bronchiolitis. The exclusion criteria consisted of previous enrollment and delay of more than 48 hours in transfer to a participating hospital after the original hospitalization. All patients were treated at the discretion of the treating physician. The institutional review board at each of the participating hospitals approved the study.

NPA collection and virology testing {#appsec1.2}
-----------------------------------

For the collection of NPAs, the child was placed supine, 1 mL of normal saline was instilled into 1 naris, and an 8-F suction catheter was used to remove the mucus. This procedure was performed once on each nostril. After the sample collection from both nares, 2 mL of normal saline was suctioned through the catheter to clear the tubing and to ensure that a standard volume of aspirate was obtained. Once collected, the NPA sample was added to the transport medium. The samples were immediately placed on ice within 1 hour of collection, and then stored at −80°C within 24 hours of collection.

PCR assay {#appsec1.3}
---------

Real-time RT-PCR was used for the detection of RNA respiratory viruses, such as rhinovirus, RSV types A and B, parainfluenza virus types 1, 2, and 3, influenza virus types A and B, 2009 novel H1N1, human metapneumovirus, coronaviruses NL-63, HKU1, OC43, and 229E, and enterovirus. Real-time PCR was used for the detection of DNA pathogens, which included adenovirus, *M pneumoniae*, and *B pertussis*. These tests are routinely conducted in Baylor College of Medicine, and details of the primers and probes have been described previously.[@bibE3], [@bibE4], [@bibE5] The upper and lower limits of rhinovirus detection were 15 and 40 CT, respectively.[@bibE6]

Statistical methods {#appsec1.4}
-------------------

For the purpose of our analyses, we focused on rhinovirus. We categorized CT values into tertiles to classify patients into 3 rhinovirus genomic load status groups: low (CT ≥ 32.7), intermediate (CT, 27.2-32.6), and high (CT \< 27.2). We compared patients\' demographic characteristics, medical history, and hospital course by rhinovirus genomic load status using chi-square or Kruskal-Wallis tests as appropriate. To examine the association of genomic load status with the outcomes, we constructed 2 logistic regression models. First, we fitted an unadjusted model that included only genomic load status as the independent variable. Second, we constructed a multivariable model adjusting for 8 patient-level variables (ie, age, sex, race, gestational age, history of wheezing, history of eczema, comorbid medical disorder, and viral coinfection status \[rhinovirus plus RSV and rhinovirus plus non-RSV pathogens\]). We chose these potential confounders on the basis of clinical plausibility and *a priori* knowledge.[@bibE1], [@bibE2], [@bibE7] We did not adjust for markers for acute severity (eg, vital signs and retractions) or duration of symptoms before bronchiolitis hospitalization because these were considered as intermediate factors in the association of interest. In both models, we used generalized estimating equations to account for patient clustering at the hospital level.

We performed a series of sensitivity analyses to assess the robustness of our findings. First, we examined the association of rhinovirus genomic load and the primary outcome, modeling the CT value as a continuous variable, in the US cohort and the Finnish cohort separately. Second, after confirming a similar association in both the cohorts, we combined the US and Finnish data set, and then repeated the analysis by using a more restrictive definition of children with bronchiolitis---that is, those younger than 12 months and without history of wheezing. Third, we stratified the analysis by coinfection status (rhinovirus only, rhinovirus plus RSV, and rhinovirus plus non-RSV pathogens). Last, we also stratified the analysis by children\'s atopic status (ie, history of eczema). All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). Results are presented as proportions with 95% CIs, medians with interquartile ranges, and odds ratios with 95% CIs. All *P* values were 2-tailed, with *P* \< .05 considered statistically significant.

Results {#appsec2}
=======

Patients\' characteristics {#appsec2.1}
--------------------------

Among the analytic cohort of 694 children, 259 children (37%) had bronchiolitis with rhinovirus only and 435 (63%) had bronchiolitis with 2 or more viruses. More specifically, 297 (43%) had rhinovirus plus RSV and 138 (20%) had rhinovirus plus non-RSV pathogens. The median hospital LOS was 2 days (interquartile range, 1-4 days). Of the 694 children in the analytic cohort, 234 children (34%) were categorized into the low rhinovirus genomic load group, 230 children (33%) into the intermediate load group, and 230 children (33%) into the high load group. Fig E1The relation between rhinovirus CT value and hospital LOS in US **(A)** and Finnish **(B)** cohorts of children with bronchiolitis.Table E1Principal investigators at the 19 participating sites in MARC-30MARC-30 US sites Besh Barcega, MDLoma Linda University Children\'s Hospital, Loma Linda, Calif John Cheng, MD, and Carlos Delgado, MDChildren\'s Healthcare of Atlanta at Egleston, Atlanta, Ga Dorothy Damore, MD, and Nikhil Shah, MDNew York Presbyterian Hospital, New York, NY Haitham Haddad, MDRainbow Babies & Children\'s Hospital, Cleveland, Ohio Paul Hain, MD, and Mark Riederer, MDMonroe Carell Jr. Children\'s Hospital at Vanderbilt, Nashville, Tenn Frank LoVecchio, DOMaricopa Medical Center, Phoenix, Ariz Charles Macias, MD, MPHTexas Children\'s Hospital, Houston, Tex Jonathan Mansbach, MD, MPHBoston Children\'s Hospital, Boston, Mass Eugene Mowad, MDAkron Children\'s Hospital, Akron, Ohio Brian Pate, MDChildren\'s Mercy Hospital & Clinics, Kansas City, Mo M. Jason Sanders, MDChildren\'s Memorial Hermann Hospital, Houston, Tex Alan Schroeder, MDSanta Clara Valley Medical Center, San Jose, Calif Michelle Stevenson, MD, MSKosair Children\'s Hospital, Louisville, Ky Erin Stucky Fisher, MDRady Children\'s Hospital, San Diego, Calif Stephen Teach, MD, MPHChildren\'s National Medical Center, Washington, DC Lisa Zaoutis, MDChildren\'s Hospital of Philadelphia, Philadelphia, PaMARC-30 Finland sites Tuomas Jartti, MDTurku University Hospital, Turku, Finland Matti Korppi, MDTampere University Hospital, Tampere, Finland Sami Remes, MDKuopio University Hospital, Kuopio, FinlandTable E2Demographic characteristics and medical history of children hospitalized with rhinovirus bronchiolitis by genomic load categoryCharacteristicVirus genomic load[∗](#tblE2fnlowast){ref-type="table-fn"}Low (n = 234)Intermediate (n = 230)High (n = 230)*P* valueAge (mo).15 \<235 (15)45 (20)42 (18) 2-5.979 (34)66 (29)66 (29) 6-11.973 (31)54 (24)71 (31) 12-23.947 (20)65 (28)51 (22)Sex: male144 (62)158 (69)136 (59).09Race/ethnicity\<.001 Non-Hispanic white80 (34)124 (54)118 (51) Non-Hispanic black71 (30)42 (18)38 (17) Hispanic72 (31)58 (25)70 (30) Other11 (5)6 (3)4 (2)Insurance.52 Nonprivate154 (66)162 (70)160 (70) Private80 (34)68 (30)70 (30)Family history of asthma.36 Neither parent152 (65)153 (67)166 (72) Either mother or father66 (28)66 (29)56 (24) Both parents10 (4)8 (4)4 (2) Unknown/missing6 (3)3 (1)4 (2)Maternal smoking during pregnancy41 (18)38 (17)37 (16).91Gestational age.84 \<32 wk16 (7)21 (9)16 (7) 32-36 wk41 (18)42 (18)41 (18) ≥37 wk or "full term"173 (74)160 (70)171 (74)Is or was breast-fed147 (63)149 (65)159 (69).34History of wheezing74 (32)82 (36)77 (34).66History of eczema62 (27)34 (15)52 (23).006History of intubation24 (10)22 (10)28 (12).64Major, relevant, comorbid medical disorder[†](#tblE2fndagger){ref-type="table-fn"}65 (28)48 (21)48 (21).12Cohort\<.001 United States211 (90)176 (77)177 (77) Finland23 (10)54 (23)53 (23)[^1][^2][^3]Table E3Clinical course of children hospitalized with rhinovirus bronchiolitis by genomic load categoryCharacteristicVirus genomic load[∗](#tblE3fnlowast){ref-type="table-fn"}*P* valueLow (n = 234)Intermediate (n = 230)High (n = 230)When difficulty breathing began (prehospitalization).10 ≥1 d66 (28)74 (32)87 (38) \<1 d160 (68)153 (67)135 (59) No difficulty prehospitalization8 (3)3 (1)8 (3)Presence of apnea (chart)14 (6)13 (6)15 (7).92Weight (kg), median (IQR)7.3 (5.1-9.5)7.0 (4.7-10.0)7.3 (4.7-9.6).92Pulse (bpm), median (IQR)160 (144-176)160 (144-173)160 (147-176).94Respiratory rate per minute, median (IQR)48 (40-60)50 (40-60)48 (40-58).86Oxygen saturation by pulse oximetry or ABG.81 \<90%32 (14)31 (13)24 (10) 90% to 93.9%40 (17)39 (17)41 (18) ≥94%155 (66)155 (68)163 (71)Retractions.68 None33 (14)44 (19)36 (16) Mild94 (40)83 (36)85 (40) Moderate or severe88 (38)91 (40)85 (37) Missing19 (8)12 (5)24 (10)Oral intake.01 Adequate102 (44)132 (57)123 (53) Inadequate96 (41)68 (30)82 (36) Missing36 (15)30 (13)25 (11)Coinfection\<.001 Rhinovirus + RSV131 (56)97 (42)69 (30) Rhinovirus + non-RSV pathogens36 (15)47 (20)55 (24) Sole rhinovirus infection67 (29)86 (37)106 (46)Length of stay (d), median (IQR)2 (1-4)2 (1-4)2 (1-3).39 ≥396 (41)85 (37)79 (34).33Intensive care treatment39 (17)30 (13)33 (14).71 Intubation and/or CPAP20 (9)12 (5)11 (5).20 Intensive care unit admission37 (16)29 (13)30 (13).65[^4][^5][^6]Table E4Unadjusted and multivariable associations of rhinovirus genomic load with bronchiolitis outcomesOutcome and rhinovirus genomic load categoryUnadjusted model[∗](#tblE4fnlowast){ref-type="table-fn"}Adjusted model[†](#tblE4fndagger){ref-type="table-fn"}Sensitivity analysis[‡](#tblE4fnddagger){ref-type="table-fn"}OR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueLength of stay ≥3 d LowReference---Reference---Reference--- Intermediate0.85 (0.56-1.29).781.07 (0.75-1.54).700.89 (0.58-1.37).60 High0.96 (0.73-1.27).431.05 (0.65-1.68).850.92 (0.63-1.34).65Intensive care treatment LowReference---Reference---Reference--- Intermediate0.89 (0.58-1.37).600.97 (0.67-1.40).870.69 (0.30-1.54).36 High0.92 (0.63-1.34).650.78 (0.43-1.40).400.84 (0.45-1.55).58[^7][^8][^9][^10]Table E5Unadjusted and multivariable associations of rhinovirus genomic load with bronchiolitis outcomes, according to the coinfection statusOutcome and rhinovirus genomic load categoryRhinovirus onlyRhinovirus plus RSVRhinovirus plus non-RSV pathogensUnadjusted model[∗](#tblE5fnlowast){ref-type="table-fn"}Adjusted model[†](#tblE5fndagger){ref-type="table-fn"}Unadjusted model[∗](#tblE5fnlowast){ref-type="table-fn"}Adjusted model[†](#tblE5fndagger){ref-type="table-fn"}Unadjusted model[∗](#tblE5fnlowast){ref-type="table-fn"}Adjusted model[†](#tblE5fndagger){ref-type="table-fn"}OR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueLength of stay ≥3 d LowReference---Reference---Reference---Reference---Reference---Reference--- Intermediate0.97 (0.52-1.82).921.24 (0.50-3.06).641.02 (0.68-1.52).941.12 (0.79-1.59).531.63 (0.80-3.33).182.44 (1.06-5.63).04 High1.17 (0.61-2.25).631.27 (0.62-2.59).520.86 (0.52-1.43).560.83 (0.45-1.55).571.52 (0.54-4.26).432.25 (0.86-5.90).10Intensive care treatment LowReference---Reference---Reference---Reference---Reference---Reference--- Intermediate0.98 (0.28-3.44).981.06 (0.22-5.12).940.84 (0.50-1.44).530.56 (0.32-0.98).040.69 (0.21-2.29).540.97 (0.40-2.43).95 High1.06 (0.52-2.16).881.07 (0.37-3.07).900.90 (0.59-1.37).610.88 (0.54-1.43).600.77 (0.21-2.83).691.23 (0.43-3.51).70[^11][^12][^13]Table E6Unadjusted and multivariable associations of rhinovirus genomic load with bronchiolitis outcomes in atopic children[∗](#tblE6fnlowast){ref-type="table-fn"} (n = 148)Outcome and rhinovirus genomic load categoryUnadjusted model[†](#tblE6fndagger){ref-type="table-fn"}Adjusted model[‡](#tblE6fnddagger){ref-type="table-fn"}OR (95% CI)*P* valueOR (95% CI)*P* valueLength of stay ≥3 d (n = 51 for outcome) LowReference---Reference--- Intermediate0.50 (0.28-0.88).020.35 (0.13-0.91).03 High0.57 (0.31-1.02).060.61 (0.26-1.40).24Intensive care treatment (n = 15 for outcome) LowReference---Reference--- Intermediate0.39 (0.08-1.89).240.12 (0.02-0.81).03 High0.67 (0.21-2.16).510.55 (0.12-2.60).45[^14][^15][^16][^17]Table E7Unadjusted and multivariable associations of rhinovirus genomic load with bronchiolitis outcomes in nonatopic children[∗](#tblE7fnlowast){ref-type="table-fn"} (n = 546)Outcome and rhinovirus genomic load categoryUnadjusted model[†](#tblE7fndagger){ref-type="table-fn"}Adjusted model[‡](#tblE7fnddagger){ref-type="table-fn"}OR (95% CI)*P* valueOR (95% CI)*P* valueLength of stay ≥3 d (n = 209 for outcome) LowReference---Reference--- Intermediate1.05 (0.74-1.50).781.18 (0.81-1.71).39 High0.95 (0.56-1.60).841.12 (0.62-2.04).70Intensive care treatment (n = 87 for outcome) LowReference---Reference--- Intermediate0.89 (0.53-1.50).670.74 (0.39-1.41).36 High0.88 (0.60-1.29).510.86 (0.59-1.27).46[^18][^19][^20][^21]Table E8Unadjusted and multivariable associations of rhinovirus genomic load with bronchiolitis outcomes in children without comorbid medical disorder (n = 528)Outcome and rhinovirus genomic load categoryUnadjusted model[∗](#tblE8fnlowast){ref-type="table-fn"}Adjusted model[†](#tblE8fndagger){ref-type="table-fn"}OR (95% CI)*P* valueOR (95% CI)*P* valueLength of stay ≥3 d (n = 198 for outcome) LowReference---Reference--- Intermediate0.88 (0.64-1.22).441.00 (0.69-1.44).99 High0.82 (0.52-1.30).401.07 (0.68-1.70).77Intensive care treatment (n = 81 for outcome) LowReference---Reference--- Intermediate0.88 (0.52-1.49).630.80 (0.37-1.73).57 High0.93 (0.69-1.26).640.99 (0.60-1.63).98[^22][^23][^24]Table E9Unadjusted and multivariable associations of rhinovirus genomic load with respiratory distress severity score[∗](#tblE9fnlowast){ref-type="table-fn"}[†](#tblE9fndagger){ref-type="table-fn"} at presentation (n = 694)Rhinovirus genomic load categoryUnadjusted model[†](#tblE9fndagger){ref-type="table-fn"}Adjusted model[‡](#tblE9fnddagger){ref-type="table-fn"}*β* Coefficient (95% CI)*P* value*β* Coefficient (95% CI)*P* valueLowReference---Reference---Intermediate0.03 (0.47-0.40).880.02 (0.42-0.45).94High0.11 (0.55-0.34).640.14 (0.31-0.59).55[^25][^26][^27]
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[^1]: Data are expressed as n (%) unless otherwise indicated.

[^2]: Categorized CT values into tertiles to classify patients into 3 rhinovirus genomic load status groups: low (CT ≥ 32.7), intermediate (CT, 27.2-32.6), and high (CT \< 27.2).

[^3]: Defined by respiratory, cardiac, neurologic, gastrointestinal, and immunologic diseases.

[^4]: Data are expressed as n (%) unless otherwise indicated.

[^5]: *ABG*, Arterial blood gas; *bpm*, beats per minute; *CPAP*, continuous positive airway pressure; *IQR*, interquartile range.

[^6]: Categorized CT values into tertiles to classify patients into 3 rhinovirus genomic load status groups: low (CT ≥ 32.7), intermediate (CT, 27.2-32.6), and high (CT \< 27.2).

[^7]: *OR*, Odds ratio.

[^8]: Unadjusted model adjusting for clustering of patients within the sites using the generalized estimating equations.

[^9]: Multivariable model adjusting for 8 patient-level variables (age, sex, race, gestational age, history of wheezing, history of eczema, comorbid medical disorder, and viral coinfection status \[rhinovirus plus RSV and rhinovirus plus non-RSV pathogens\]) and clustering of patients within the sites.

[^10]: Multivariable model using a restrictive definition of children with bronchiolitis---ie, those younger than 12 months and without history of wheezing (n = 389).

[^11]: *OR*, Odds ratio.

[^12]: Unadjusted model adjusting for clustering of patients within the sites using the generalized estimating equations.

[^13]: Multivariable model adjusting for 7 patient-level variables (age, sex, race, gestational age, history of wheezing, history of eczema, and comorbid medical disorder) and clustering of patients within the sites.
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